Related Experiment Video
Updated: May 3, 2026
The Utilization of Oropharyngeal Intratracheal PAMP Administration and Bronchoalveolar Lavage to Evaluate the Host Immune Response in Mice
Published on: April 3, 2014
Elevated secretion of myeloperoxidase by neutrophils from asthmatic patients: the effect of immunotherapy
J Monteseirín1, I Bonilla, J Camacho
1Departamento de Medicina, Servicio Regional de Inmunología y Alergia, Hospital Universitario Virgen Macarena, Universidad de Sevilla, Seville, Spain.
Background:
There is increasing evidence of neutrophil participation in asthma and the allergic process. After activation, neutrophils release myeloperoxidase (MPO) together with other granule enzymes.
Objectives:
In this study we attempted to evaluate the release of MPO in vitro by neutrophils from asthmatic patients and the relationship between neutrophil degranulation and lung function, measured as FEV(1), of the patients. We also investigated the possible role of immunotherapy in the release of MPO by neutrophils.
Methods:
Neutrophils were stimulated with formyl-methionyl-leucyl-phenylalanine for 45 minutes at 37 degrees C. MPO released from neutrophils was assayed by using an MPO enzyme immunoassay.
Results:
Neutrophils released statistically significantly higher MPO levels in the asthmatic patients not receiving immunotherapy than in the healthy group. A significant inverse correlation was observed in the asthmatic group not receiving immunotherapy between MPO secretion and lung function, measured as FEV(1), of the patients. Neutrophils of the asthmatic group receiving immunotherapy released significantly less MPO than did those of the asthmatic group not receiving immunotherapy, with MPO levels equal to those from nonallergic subjects.
Conclusions:
We conclude that neutrophils obtained from allergic asthmatic patients have an increased propensity to release MPO. The experiments described here provide evidence that there is a significant inverse relationship between levels of MPO released by neutrophils from allergic patients and lung function, as assessed by FEV(1). Our study suggests that immunotherapy actively modifies the release of MPO in vitro by neutrophils from allergic asthmatic patients.
Insights
Neutrophils from allergic asthma patients release more myeloperoxidase (MPO), an enzyme linked to reduced lung function. Immunotherapy significantly lowers MPO release, suggesting a role in managing asthma.
Area of Science:
- Immunology
- Pulmonology
- Biochemistry
Background:
- Growing evidence implicates neutrophils in asthma and allergic reactions.
- Activated neutrophils release myeloperoxidase (MPO) and other granule enzymes.
Purpose of the Study:
- To evaluate in vitro MPO release by neutrophils from asthma patients.
- To determine the relationship between neutrophil degranulation and lung function (FEV1).
- To investigate the impact of immunotherapy on neutrophil MPO release.
Main Methods:
- Neutrophils were stimulated with formyl-methionyl-leucyl-phenylalanine.
- MPO release was quantified using an MPO enzyme immunoassay.
- Measurements were taken from asthmatic patients (with and without immunotherapy) and healthy controls.
Main Results:
- Asthmatic patients not on immunotherapy showed significantly higher MPO release than healthy individuals.
- A significant inverse correlation was found between MPO secretion and FEV1 in untreated asthmatics.
- Asthmatic patients receiving immunotherapy exhibited reduced MPO release, comparable to non-allergic subjects.
Conclusions:
- Neutrophils from allergic asthmatics demonstrate an elevated MPO release propensity.
- Increased MPO levels correlate inversely with lung function (FEV1) in allergic asthma.
- Immunotherapy appears to modulate MPO release from neutrophils in allergic asthmatics.
Related Concept Videos
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
01:26Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
01:28Asthma I: Introduction